NAMZARIC can provide combination therapy without having to add more pills†
NAMENDA® (memantine HCl) twice daily or NAMENDA XR® (memantine HCl).
The dose will gradually increase from 7 mg/10 mg to the maximum dose of 28 mg/10 mg over 4 weeks.
If the doctor thinks NAMZARIC is right for your loved one, they may give them a Starter Pack to help transition to NAMZARIC
Your loved one can get started on NAMZARIC by following this schedule:
Taken once daily in the evening. The dose of NAMZARIC will gradually increase over 4 weeks
Your loved one should stay on the same dose for at least 7 days
The dose should only be increased if the previous dose was well tolerated
Color-coded capsules help your loved one reach the recommended target dose (28 mg/10 mg once daily)
If your loved one is taking donepezil HCl 10 mg and NAMENDA® (memantine HCl) twice daily or once-a-day NAMENDA XR® (memantine HCl), ask their doctor if NAMZARIC is right for them
Currently taking NAMENDA and donepezil?
The doctor may instruct you to transition your loved one directly to once-a-day NAMZARIC the day after their last dose of NAMENDA and donepezil.
Currently taking NAMENDA XR and donepezil?
The doctor may instruct you to transition your loved one directly to once-a-day NAMZARIC the day after their last dose of NAMENDA XR and donepezil.
NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer’s disease in patients who are taking donepezil hydrochloride 10 mg, the active ingredient in Aricept®.
There is no evidence that NAMZARIC prevents or slows the underlying disease process in patients with Alzheimer's disease.
NAMZARIC should not be taken by anyone who: has an allergy to memantine HCl, donepezil HCl, medicines that contain piperidines, or any of the ingredients in NAMZARIC.
Before taking NAMZARIC, tell the doctor about all of the patient’s medical conditions, including:
Tell the doctor about all the medicines the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
NAMZARIC may cause serious side effects, including:
The most common side effects of memantine HCl include: headache, diarrhea, and dizziness.
The most common side effects of donepezil HCl include: diarrhea, not wanting to eat (anorexia), and bruising.
These are not all the possible side effects of NAMZARIC.
Please see full Prescribing Information, including Patient Information.
Aricept® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer’s disease in patients who are taking donepezil hydrochloride 10 mg, the active ingredient in Aricept®.
There is no evidence that NAMZARIC prevents or slows the underlying disease process in patients with Alzheimer's disease.
NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer’s disease in patients who are taking donepezil hydrochloride 10 mg, the active ingredient in Aricept®.
There is no evidence that NAMZARIC prevents or slows the underlying disease process in patients with Alzheimer's disease.
NAMZARIC should not be taken by anyone who: has an allergy to memantine HCl, donepezil HCl, medicines that contain piperidines, or any of the ingredients in NAMZARIC.
Before taking NAMZARIC, tell the doctor about all of the patient’s medical conditions, including:
Tell the doctor about all the medicines the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
NAMZARIC may cause serious side effects, including:
The most common side effects of memantine HCl include: headache, diarrhea, and dizziness.
The most common side effects of donepezil HCl include: diarrhea, not wanting to eat (anorexia), and bruising.
These are not all the possible side effects of NAMZARIC.
NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer’s disease in patients who are taking donepezil hydrochloride 10 mg, the active ingredient in Aricept®.
Please see full Prescribing Information, including Patient Information.
Aricept® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.